Literature DB >> 371419

Platelet monoamine oxidase activity in schizophrenia: a review of the data.

R J Wyatt, S G Potkin, D L Murphy.   

Abstract

The authors review studies of platelet and white cell monoamine oxidase (MAO) activity in schizophrenic patients. The data on acute schizophrenic patients remain inconclusive. Review of 26 reports of chronic schizophrenic patients leaves little doubt, however, that there is a subgroup in which the enzyme activity is decreased. Despite the strong association of decreased MAO activity and chronic schizophrenia, the etiological relationship of low platelet MAO activity to schizophrenia has not been demonstrated. More complete diagnostic descriptions will shed light on precisely which patients have lowered MAO activity. Further metabolic investigations with such patients are needed to determine the physiological significance of this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371419

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  13 in total

1.  Neurochemical and genetic bases of psychopathology: current status.

Authors:  S S Kety
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

2.  An overview of the genetics of psychopathology.

Authors:  D R Petersen; A C Collins; R G Miles
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

3.  The specific activity of platelet monoamine oxidase varies with platelet count during severe exercise and noradrenaline infusion.

Authors:  M J Gawel; V Glover; M Burkitt; M Sandler; F C Rose
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Platelet monoamine oxidase in healthy subjects: the "biochemical high-risk paradigm" revisited.

Authors:  P Propping; E R Rey; W Friedl; H Beckmann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1981

5.  Platelet monoamine oxidase activity in megaloblastic anaemia.

Authors:  V Glover; M Sandler; A Hughes; A V Hoffbrand
Journal:  J Clin Pathol       Date:  1980-10       Impact factor: 3.411

6.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  Serum dopamine-beta-hydroxylase activity: clinical applications in child psychiatry.

Authors:  J G Young; R M Kyprie; N T Ross; D J Cohen
Journal:  J Autism Dev Disord       Date:  1980-03

8.  Clinical variables and platelet mao in schizophrenia.

Authors:  I Sharma; A Kumar; J P Chansouria; S L Varma
Journal:  Indian J Psychiatry       Date:  1991-10       Impact factor: 1.759

9.  Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics.

Authors:  J J Mann; R D Kaplan; A Georgotas; E Friedman; M Branchey; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Low platelet MAO activity in chronic schizophrenics: a long-term effect of neuroleptic treatment?

Authors:  M Del Vecchio; M Maj; A D'Ambrosio; D Kemali
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.